CALCA and Hypertension: Wang et al.'s retrospective cohort study provides particularly valuable insights into real-world clinical practice, demonstrating that patients with baseline hypertension experienced a 3.7% annual increase in antihypertensive medication requirements when treated with anti-CGRP therapies [13].